ALK fusions were predominantly observed in lung cancer and lymphoma, while RET, ABL1, and BRAF fusions have been identified most frequently in thyroid cancer, leukemias, and pediatric low-grade gliomas, respectively. This evidence concerns the gene BRAF and thyroid gland carcinoma.